Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. / Hersby, Ditte Stampe; Schejbel, Lone; Breinholt, Marie Fredslund; Høgdall, Estrid; Nørgaard, Peter; Dencker, Ditte; Nielsen, Torsten Holm; Pedersen, Lars Møller; Gang, Anne Ortved.

In: Leukemia and Lymphoma, Vol. 64, No. 9, 2023, p. 1527-1535.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hersby, DS, Schejbel, L, Breinholt, MF, Høgdall, E, Nørgaard, P, Dencker, D, Nielsen, TH, Pedersen, LM & Gang, AO 2023, 'Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 64, no. 9, pp. 1527-1535. https://doi.org/10.1080/10428194.2023.2220454

APA

Hersby, D. S., Schejbel, L., Breinholt, M. F., Høgdall, E., Nørgaard, P., Dencker, D., Nielsen, T. H., Pedersen, L. M., & Gang, A. O. (2023). Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma, 64(9), 1527-1535. https://doi.org/10.1080/10428194.2023.2220454

Vancouver

Hersby DS, Schejbel L, Breinholt MF, Høgdall E, Nørgaard P, Dencker D et al. Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma. 2023;64(9):1527-1535. https://doi.org/10.1080/10428194.2023.2220454

Author

Hersby, Ditte Stampe ; Schejbel, Lone ; Breinholt, Marie Fredslund ; Høgdall, Estrid ; Nørgaard, Peter ; Dencker, Ditte ; Nielsen, Torsten Holm ; Pedersen, Lars Møller ; Gang, Anne Ortved. / Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2023 ; Vol. 64, No. 9. pp. 1527-1535.

Bibtex

@article{8957310137964108acc0ced2b039d322,

title = "Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma",

abstract = "Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, both regarding clinical presentation, response to treatment and outcome. Recently, subclassification of DLBCL based on mutational profile has been suggested, and next generation sequencing (NGS) analysis may be relevant as part of the diagnostic workflow. This will, however, often be based on analysis of one tumor biopsy. Here, we present a prospective study where multi-site sampling was performed prior to treatment in patients with newly diagnosed DLBCL. Two spatially different biopsies from 16 patients were analyzed using NGS with an in-house 59-gene lymphoma panel. In 8/16 (50%) patients, mutational differences were found between the two biopsy sites, including differences in TP53 mutational status. Our data indicate that a biopsy from the extra-nodal site may represent the most advanced clone, and an extra-nodal biopsy should be preferred for analysis, if safely accessible. This will help ensure a standardized stratification and treatment decision.",

keywords = "diffuse large B-cell, extra-nodal, Genetic heterogeneity, lymphoma, TP53",

author = "Hersby, {Ditte Stampe} and Lone Schejbel and Breinholt, {Marie Fredslund} and Estrid H{\o}gdall and Peter N{\o}rgaard and Ditte Dencker and Nielsen, {Torsten Holm} and Pedersen, {Lars M{\o}ller} and Gang, {Anne Ortved}",

note = "Publisher Copyright: {\textcopyright} 2023 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/10428194.2023.2220454",

language = "English",

volume = "64",

pages = "1527--1535",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "9",

}

RIS

TY - JOUR

T1 - Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma

AU - Hersby, Ditte Stampe

AU - Schejbel, Lone

AU - Breinholt, Marie Fredslund

AU - Høgdall, Estrid

AU - Nørgaard, Peter

AU - Dencker, Ditte

AU - Nielsen, Torsten Holm

AU - Pedersen, Lars Møller

AU - Gang, Anne Ortved

PY - 2023

Y1 - 2023

N2 - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, both regarding clinical presentation, response to treatment and outcome. Recently, subclassification of DLBCL based on mutational profile has been suggested, and next generation sequencing (NGS) analysis may be relevant as part of the diagnostic workflow. This will, however, often be based on analysis of one tumor biopsy. Here, we present a prospective study where multi-site sampling was performed prior to treatment in patients with newly diagnosed DLBCL. Two spatially different biopsies from 16 patients were analyzed using NGS with an in-house 59-gene lymphoma panel. In 8/16 (50%) patients, mutational differences were found between the two biopsy sites, including differences in TP53 mutational status. Our data indicate that a biopsy from the extra-nodal site may represent the most advanced clone, and an extra-nodal biopsy should be preferred for analysis, if safely accessible. This will help ensure a standardized stratification and treatment decision.

AB - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, both regarding clinical presentation, response to treatment and outcome. Recently, subclassification of DLBCL based on mutational profile has been suggested, and next generation sequencing (NGS) analysis may be relevant as part of the diagnostic workflow. This will, however, often be based on analysis of one tumor biopsy. Here, we present a prospective study where multi-site sampling was performed prior to treatment in patients with newly diagnosed DLBCL. Two spatially different biopsies from 16 patients were analyzed using NGS with an in-house 59-gene lymphoma panel. In 8/16 (50%) patients, mutational differences were found between the two biopsy sites, including differences in TP53 mutational status. Our data indicate that a biopsy from the extra-nodal site may represent the most advanced clone, and an extra-nodal biopsy should be preferred for analysis, if safely accessible. This will help ensure a standardized stratification and treatment decision.

KW - diffuse large B-cell

KW - extra-nodal

KW - Genetic heterogeneity

KW - lymphoma

KW - TP53

U2 - 10.1080/10428194.2023.2220454

DO - 10.1080/10428194.2023.2220454

M3 - Journal article

C2 - 37328933

AN - SCOPUS:85162055122

VL - 64

SP - 1527

EP - 1535

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -

ID: 366303702